<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="PubMed-not-MEDLINE" Owner="NLM"><PMID Version="1">38327277</PMID><DateRevised><Year>2024</Year><Month>02</Month><Day>10</Day></DateRevised><Article PubModel="Electronic-eCollection"><Journal><ISSN IssnType="Electronic">2667-193X</ISSN><JournalIssue CitedMedium="Internet"><Volume>30</Volume><PubDate><Year>2024</Year><Month>Feb</Month></PubDate></JournalIssue><Title>Lancet regional health. Americas</Title><ISOAbbreviation>Lancet Reg Health Am</ISOAbbreviation></Journal><ArticleTitle>Prevalence and determinants of post-acute sequelae after SARS-CoV-2 infection (Long COVID) among adults in Mexico during 2022: a retrospective analysis of nationally representative data.</ArticleTitle><Pagination><StartPage>100688</StartPage><MedlinePgn>100688</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">100688</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.lana.2024.100688</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="UNASSIGNED">Post-acute sequelae after SARS-CoV-2 infection (PASC) remains a concerning long-term complication of COVID-19. Here, we aimed to characterize the epidemiology of PASC in Mexico during 2022 and identify potential associations of covariates with PASC prevalence using nationally representative data.</AbstractText><AbstractText Label="METHODS" NlmCategory="UNASSIGNED">We analyzed data from the 2022 Mexican National Health and Nutrition Survey (ENSANUT) from 24,434 participants, representing 85,521,661 adults &#x2265;20 years. PASC was defined using both the National Institute for Health and Care Excellence (NICE) definition and a PASC score &#x2265;12. Estimates of PASC prevalence were stratified by age, sex, rural vs. urban setting, social lag quartiles, number of reinfections, vaccination status and periods of predominance of SARS-CoV-2 circulating variants. Determinants of PASC were assessed using log-binomial regression models adjusted by survey weights.</AbstractText><AbstractText Label="FINDINGS" NlmCategory="UNASSIGNED">Persistent symptoms after SARS-CoV-2 infection were reported by 12.44% (95% CI 11.89-12.99) of adults &#x2265;20 years in Mexico in 2022. The most common persistent symptoms were fatigue, musculoskeletal pain, headache, cough, loss of smell or taste, fever, post-exertional malaise, brain fog, anxiety, and chest pain. PASC was present in 21.21% (95% CI 19.74-22.68) of subjects with previously diagnosed COVID-19. Over 28.6% of patients with PASC reported symptoms persistence &#x2265;6 months and 14.05% reported incapacitating symptoms. Higher PASC prevalence was associated with SARS-CoV-2 reinfections, depressive symptoms and living in states with high social lag. PASC prevalence, particularly its more severe forms, decreased with COVID-19 vaccination and for infections during periods of Omicron variant predominance.</AbstractText><AbstractText Label="INTERPRETATION" NlmCategory="UNASSIGNED">PASC remains a significant public health burden in Mexico as the COVID-19 pandemic transitions into endemic. Promoting SARS-CoV-2 reinfection prevention and booster vaccination may be useful in reducing PASC burden.</AbstractText><AbstractText Label="FUNDING" NlmCategory="UNASSIGNED">This research was supported by Instituto Nacional de Geriatr&#xed;a in Mexico.</AbstractText><CopyrightInformation>&#xa9; 2024 The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Bello-Chavolla</LastName><ForeName>Omar Yaxmehen</ForeName><Initials>OY</Initials><AffiliationInfo><Affiliation>Research Division, Instituto Nacional de Geriatr&#xed;a, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ferm&#xed;n-Mart&#xed;nez</LastName><ForeName>Carlos A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Research Division, Instituto Nacional de Geriatr&#xed;a, Mexico City, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>MD/PhD (PECEM) Program, Facultad de Medicina, Universidad Nacional Aut&#xf3;noma de M&#xe9;xico, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ram&#xed;rez-Garc&#xed;a</LastName><ForeName>Daniel</ForeName><Initials>D</Initials><AffiliationInfo><Affiliation>Research Division, Instituto Nacional de Geriatr&#xed;a, Mexico City, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Facultad de Medicina, Universidad Nacional Aut&#xf3;noma de M&#xe9;xico, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vargas-V&#xe1;zquez</LastName><ForeName>Arsenio</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Facultad de Medicina, Universidad Nacional Aut&#xf3;noma de M&#xe9;xico, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fern&#xe1;ndez-Chirino</LastName><ForeName>Luisa</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Research Division, Instituto Nacional de Geriatr&#xed;a, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Basile-Alvarez</LastName><ForeName>Mart&#xed;n Roberto</ForeName><Initials>MR</Initials><AffiliationInfo><Affiliation>Research Division, Instituto Nacional de Geriatr&#xed;a, Mexico City, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Facultad de Medicina, Universidad Nacional Aut&#xf3;noma de M&#xe9;xico, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>S&#xe1;nchez-Castro</LastName><ForeName>Paulina</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Research Division, Instituto Nacional de Geriatr&#xed;a, Mexico City, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Facultad de Medicina, Universidad Nacional Aut&#xf3;noma de M&#xe9;xico, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>N&#xfa;&#xf1;ez-Luna</LastName><ForeName>Alejandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Research Division, Instituto Nacional de Geriatr&#xed;a, Mexico City, Mexico.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Facultad de Medicina, Universidad Nacional Aut&#xf3;noma de M&#xe9;xico, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Antonio-Villa</LastName><ForeName>Neftali Eduardo</ForeName><Initials>NE</Initials><AffiliationInfo><Affiliation>Department of Endocrinology, Instituto Nacional de Cardiolog&#xed;a Ignacio Ch&#xe1;vez, Mexico City, Mexico.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>02</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Lancet Reg Health Am</MedlineTA><NlmUniqueID>9918232503006676</NlmUniqueID><ISSNLinking>2667-193X</ISSNLinking></MedlineJournalInfo><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">Long COVID</Keyword><Keyword MajorTopicYN="N">Mexico</Keyword><Keyword MajorTopicYN="N">PASC</Keyword><Keyword MajorTopicYN="N">Sequelae</Keyword></KeywordList><CoiStatement>Nothing to disclose.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2023</Year><Month>7</Month><Day>19</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2023</Year><Month>12</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>1</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>2</Month><Day>8</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>2</Month><Day>8</Day><Hour>4</Hour><Minute>3</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>2</Month><Day>3</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38327277</ArticleId><ArticleId IdType="pmc">PMC10847769</ArticleId><ArticleId IdType="doi">10.1016/j.lana.2024.100688</ArticleId><ArticleId IdType="pii">S2667-193X(24)00015-2</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Davis H.E., McCorkell L., Vogel J.M., Topol E.J. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133&#x2013;146.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9839201</ArticleId><ArticleId IdType="pubmed">36639608</ArticleId></ArticleIdList></Reference><Reference><Citation>Sudre C.H., Murray B., Varsavsky T., et al. Attributes and predictors of long COVID. Nat Med. 2021;27(4):626&#x2013;631.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7611399</ArticleId><ArticleId IdType="pubmed">33692530</ArticleId></ArticleIdList></Reference><Reference><Citation>Soriano J.B., Murthy S., Marshall J.C., Relan P., Diaz J.V. WHO clinical case definition working group on post-COVID-19 condition. A clinical case definition of post-COVID-19 condition by a Delphi consensus. Lancet Infect Dis. 2022;22(4):e102&#x2013;e107.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8691845</ArticleId><ArticleId IdType="pubmed">34951953</ArticleId></ArticleIdList></Reference><Reference><Citation>Venkatesan P. NICE guideline on long COVID. Lancet Respir Med. 2021;9(2):129.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7832375</ArticleId><ArticleId IdType="pubmed">33453162</ArticleId></ArticleIdList></Reference><Reference><Citation>Thaweethai T., Jolley S.E., Karlson E.W., et al. Development of a definition of postacute sequelae of SARS-CoV-2 infection. JAMA. 2023;329(22):1934&#x2013;1946.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10214179</ArticleId><ArticleId IdType="pubmed">37278994</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakhamuri S.M., Jankie S., Pereira L.M.P. Calling on Latin America and the Caribbean countries to recognise the disability from long COVID. Lancet Reg Health Am. 2022;15:100362. https://www.thelancet.com/journals/lanam/article/PIIS2667-193X(22)00179-X/fulltext [cited 2023 Jul 4] Available from:</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9412073</ArticleId><ArticleId IdType="pubmed">36043156</ArticleId></ArticleIdList></Reference><Reference><Citation>Mathieu E., Ritchie H., Rod&#xe9;s-Guirao L., et al.   Our World in Data; 2020. Coronavirus Pandemic (COVID-19)https://ourworldindata.org/coronavirus/country/mexico [cited 2023 Jul 4]; Available from:</Citation></Reference><Reference><Citation>Antonio-Villa N.E., Bello-Chavolla O.Y., Ferm&#xed;n-Mart&#xed;nez C.A., et al. Socio-demographic inequalities and excess non-COVID-19 mortality during the COVID-19 pandemic: a data-driven analysis of 1 069 174 death certificates in Mexico. Int J Epidemiol. 2022;51(6):1711&#x2013;1721.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9619535</ArticleId><ArticleId IdType="pubmed">36174226</ArticleId></ArticleIdList></Reference><Reference><Citation>Bello-Chavolla O.Y., Bahena-L&#xf3;pez J.P., Antonio-Villa N.E., et al. Predicting mortality due to SARS-CoV-2: a mechanistic score relating obesity and diabetes to COVID-19 outcomes in Mexico. J&#xa0;Clin Endocrinol Metabolism. 2020;105(8):2752&#x2013;2761.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7313944</ArticleId><ArticleId IdType="pubmed">32474598</ArticleId></ArticleIdList></Reference><Reference><Citation>Vargas-V&#xe1;zquez A., Bello-Chavolla O.Y., Ortiz-Brizuela E., et al. Impact of undiagnosed type 2 diabetes and pre-diabetes on severity and mortality for SARS-CoV-2 infection. BMJ Open Diabetes Res Care. 2021;9(1)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7887863</ArticleId><ArticleId IdType="pubmed">33593750</ArticleId></ArticleIdList></Reference><Reference><Citation>Antonio-Villa N.E., Fernandez-Chirino L., Pisanty-Alatorre J., et al. Comprehensive evaluation of the impact of sociodemographic inequalities on adverse outcomes and excess mortality during the COVID-19 pandemic in Mexico City. Clin Infect Dis. 2021;74(5):785&#x2013;792.</Citation><ArticleIdList><ArticleId IdType="pubmed">34159351</ArticleId></ArticleIdList></Reference><Reference><Citation>Carnalla M., Basto-Abreu A., Stern D., et al. Prevalencia de anticuerpos y vacunaci&#xf3;n contra SARS-CoV-2 en 2022 en M&#xe9;xico. Salud Publica Mex. 2023;65:s135&#x2013;s145.</Citation><ArticleIdList><ArticleId IdType="pubmed">38060941</ArticleId></ArticleIdList></Reference><Reference><Citation>Bello-Chavolla O.Y., Antonio-Villa N.E., Vald&#xe9;s-Ferrer S.I., et al. Effectiveness of a nationwide COVID-19 vaccination program in Mexico against symptomatic COVID-19, hospitalizations, and death: a retrospective analysis of national surveillance data. Int J Infect Dis. 2023;129:188&#x2013;196.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9918316</ArticleId><ArticleId IdType="pubmed">36775188</ArticleId></ArticleIdList></Reference><Reference><Citation>N&#xfa;&#xf1;ez I., Gillard J., Fragoso-Saavedra S., et al.   2022. Longitudinal clinical phenotyping of post COVID condition in Mexican patients recovering from severe COVID-19: a prospective cohort study.https://papers.ssrn.com/abstract=4238650 Rochester, NY. [cited 2023 Jul 4]. Available from:</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10505811</ArticleId><ArticleId IdType="pubmed">37727759</ArticleId></ArticleIdList></Reference><Reference><Citation>Vida&#xf1;a-P&#xe9;rez D., L&#xf3;pez-Olmedo N., Gonz&#xe1;lez-Morales R., Shamah-Levy T., Barrientos-Guti&#xe9;rrez T. Prevalence of covid-19 sequelae in the national health and nutrition survey 2020. Salud Publica Mex. 2021;63(6, Nov-Dic):799&#x2013;802.</Citation><ArticleIdList><ArticleId IdType="pubmed">35099891</ArticleId></ArticleIdList></Reference><Reference><Citation>Romero-Mart&#xed;nez M., Barrientos-Guti&#xe9;rrez T., Cuevas-Nasu L., et al. Metodolog&#xed;a de la Encuesta nacional de Salud y nutrici&#xf3;n 2022 y planeaci&#xf3;n y dise&#xf1;o de la Ensanut continua 2020-2024. Salud Publica Mex. 2022;64(5, sept-oct):522&#x2013;529.</Citation><ArticleIdList><ArticleId IdType="pubmed">36130337</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xe1;nchez-P&#xe1;jaro A., Ferrer C.P., Basto-Abreu A., et al. Seroprevalencia de SARS-CoV-2 en adultos y adultos mayores en M&#xe9;xico y su asociaci&#xf3;n con enfermedades cr&#xf3;nicas. Ensanut 2020 Covid-19. Salud Publica Mex. 2021;63(6, Nov-Dic):705&#x2013;712.</Citation><ArticleIdList><ArticleId IdType="pubmed">35099898</ArticleId></ArticleIdList></Reference><Reference><Citation>Bello-Chavolla O.Y., Antonio-Villa N.E., Vargas-V&#xe1;zquez A., Ferm&#xed;n-Mart&#xed;nez C.A., M&#xe1;rquez-Salinas A., Bahena-L&#xf3;pez J.P. Profiling cases with nonrespiratory symptoms and asymptomatic severe acute respiratory syndrome coronavirus 2 infections in Mexico city. Clin Infect Dis. 2021;72(10):e655&#x2013;e658.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7499552</ArticleId><ArticleId IdType="pubmed">32857829</ArticleId></ArticleIdList></Reference><Reference><Citation>Nalbandian A., Sehgal K., Gupta A., et al. Post-acute COVID-19 syndrome. Nat Med. 2021;27(4):601&#x2013;615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8893149</ArticleId><ArticleId IdType="pubmed">33753937</ArticleId></ArticleIdList></Reference><Reference><Citation>CDC . Healthcare Workers; 2020. Centers for disease control and prevention.https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-conditions.html [cited 2023 Dec 26] Available from:</Citation></Reference><Reference><Citation>Klein J., Wood J., Jaycox J., et al.  Distinguishing features of Long COVID identified through immune profiling. medRxiv. 2022 https://www.medrxiv.org/content/10.1101/2022.08.09.22278592v1 p. 2022.08.09.22278592. [cited 2023 Jul 4] Available from:</Citation><ArticleIdList><ArticleId IdType="doi">10.1101/2022.08.09.22278592v1</ArticleId><ArticleId IdType="pmc">PMC10620090</ArticleId><ArticleId IdType="pubmed">37748514</ArticleId></ArticleIdList></Reference><Reference><Citation>Montes-Gonz&#xe1;lez J.A., Zaragoza-Jim&#xe9;nez C.A., Antonio-Villa N.E., et al. Protection of hybrid immunity against SARS-CoV-2 reinfection and severe COVID-19 during periods of Omicron variant predominance in Mexico. Front Public Health. 2023;11</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10110947</ArticleId><ArticleId IdType="pubmed">37081954</ArticleId></ArticleIdList></Reference><Reference><Citation>&#xcd;ndice Rezago Social 2020. https://www.coneval.org.mx/Medicion/IRS/Paginas/Indice_Rezago_Social_2020.aspx [cited 2023 Jul 1]. Available from:</Citation></Reference><Reference><Citation>Bello-Chavolla O.Y., Antonio-Villa N.E., Ferm&#xed;n-Mart&#xed;nez C.A., et al. Diabetes-related excess mortality in Mexico: a comparative analysis of national death registries between 2017&#x2013;2019 and 2020. Diabetes Care. 2022;45(12):2957&#x2013;2966.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7613876</ArticleId><ArticleId IdType="pubmed">36286591</ArticleId></ArticleIdList></Reference><Reference><Citation>Salinas-Rodr&#xed;guez A., Manrique-Espinoza B., Acosta-Castillo G.I., et al. [Validation of a cutoff point for the short version of the Depression Scale of the Center for Epidemiologic Studies in older Mexican adults] Salud Publica Mex. 2014;56(3):279&#x2013;285.</Citation><ArticleIdList><ArticleId IdType="pubmed">25272180</ArticleId></ArticleIdList></Reference><Reference><Citation>Salinas-Rodr&#xed;guez A., Manrique-Espinoza B., Acosta-Castillo I., et al. [Validation of a cutoff for the depression Scale of the center for epidemiologic studies, brief version (CESD-7)] Salud Publica Mex. 2013;55(3):267&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pubmed">23912539</ArticleId></ArticleIdList></Reference><Reference><Citation>survey.pdf. https://cran.r-project.org/web/packages/survey/survey.pdf [cited 2023 Apr 21]. Available from:</Citation></Reference><Reference><Citation>Goodall D.W. A&#xa0;new similarity index based on probability. Biometrics. 1966;22(4):882&#x2013;907.</Citation></Reference><Reference><Citation>Tran V.T., Perrodeau E., Saldanha J., Pane I., Ravaud P.  Social Science Research Network; Rochester, NY: 2021. Efficacy of COVID-19 vaccination on the symptoms of patients with long COVID: a target trial emulation using data from the ComPaRe e-cohort in France.https://papers.ssrn.com/abstract=3932953 Report No.: ID 3932953. [cited 2021 Oct 6] Available from:</Citation></Reference><Reference><Citation>Brannock M.D., Chew R.F., Preiss A.J., et al. Long COVID risk and pre-COVID vaccination in an EHR-based cohort study from the RECOVER program. Nat Commun. 2023;14(1):2914.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10201472</ArticleId><ArticleId IdType="pubmed">37217471</ArticleId></ArticleIdList></Reference><Reference><Citation>Ballouz T., Menges D., Anagnostopoulos A., et al. Recovery and symptom trajectories up to two years after SARS-CoV-2 infection: population based, longitudinal cohort study. BMJ. 2023;381</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10230608</ArticleId><ArticleId IdType="pubmed">37257891</ArticleId></ArticleIdList></Reference><Reference><Citation>Nasserie T., Hittle M., Goodman S.N. Assessment of the frequency and variety of persistent symptoms among patients with COVID-19: a systematic review. JAMA Netw Open. 2021;4(5)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8155823</ArticleId><ArticleId IdType="pubmed">34037731</ArticleId></ArticleIdList></Reference><Reference><Citation>Global Burden of Disease Long COVID Collaborators Estimated global proportions of individuals with persistent fatigue, cognitive, and respiratory symptom clusters following symptomatic COVID-19 in 2020 and 2021. JAMA. 2022;328(16):1604&#x2013;1615.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9552043</ArticleId><ArticleId IdType="pubmed">36215063</ArticleId></ArticleIdList></Reference><Reference><Citation>Ford N.D., Slaughter D., Edwards D., et al. Long COVID and significant activity limitation among adults, by age - United States, June 1-13, 2022, to June 7-19, 2023. MMWR Morb Mortal Wkly Rep. 2023;72(32):866&#x2013;870.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10415000</ArticleId><ArticleId IdType="pubmed">37561665</ArticleId></ArticleIdList></Reference><Reference><Citation>Angarita-Fonseca A., Torres-Castro R., Benavides-Cordoba V., et al. Exploring long COVID condition in Latin America: its impact on patients' activities and associated healthcare use. Front Med. 2023;10</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10157152</ArticleId><ArticleId IdType="pubmed">37153089</ArticleId></ArticleIdList></Reference><Reference><Citation>Lapa J., Rosa D., Mendes J.P.L., Deusdar&#xe1; R., Romero G.A.S. Prevalence and associated factors of post-COVID-19 syndrome in a Brazilian cohort after 3 and 6 Months of hospital discharge. Int J Environ Res Public Health. 2023;20(1):848.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9820092</ArticleId><ArticleId IdType="pubmed">36613170</ArticleId></ArticleIdList></Reference><Reference><Citation>Shabnam S., Razieh C., Dambha-Miller H., et al. Socioeconomic inequalities of long COVID: a retrospective population-based cohort study in the United Kingdom. J&#xa0;R Soc Med. 2023;116(8):263&#x2013;273.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10469969</ArticleId><ArticleId IdType="pubmed">37164035</ArticleId></ArticleIdList></Reference><Reference><Citation>Collin S.M., Bakken I.J., Nazareth I., Crawley E., White P.D. Trends in the incidence of chronic fatigue syndrome and fibromyalgia in the UK, 2001-2013: a Clinical Practice Research Datalink study. J&#xa0;R Soc Med. 2017;110(6):231&#x2013;244.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5499564</ArticleId><ArticleId IdType="pubmed">28358988</ArticleId></ArticleIdList></Reference><Reference><Citation>Berger Z., Altiery de Jesus V., Assoumou S.A., Greenhalgh T. Long COVID and health inequities: the role of primary care. Milbank Q. 2021;99(2):519&#x2013;541.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8241274</ArticleId><ArticleId IdType="pubmed">33783907</ArticleId></ArticleIdList></Reference><Reference><Citation>Bowe B., Xie Y., Al-Aly Z. Acute and postacute sequelae associated with SARS-CoV-2 reinfection. Nat Med. 2022;28(11):2398&#x2013;2405.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9671810</ArticleId><ArticleId IdType="pubmed">36357676</ArticleId></ArticleIdList></Reference><Reference><Citation>Doll M.K., Waghmare A., Heit A., et al. Acute and postacute COVID-19 outcomes among immunologically naive adults during delta vs Omicron waves. JAMA Netw Open. 2023;6(2)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9975921</ArticleId><ArticleId IdType="pubmed">36853602</ArticleId></ArticleIdList></Reference><Reference><Citation>Buonsenso D., Morello R., Mariani F., et al. Risk of long Covid in children infected with Omicron or pre-Omicron SARS-CoV-2 variants. Acta Paediatr. 2023;112(6):1284&#x2013;1286.</Citation><ArticleIdList><ArticleId IdType="pubmed">36938946</ArticleId></ArticleIdList></Reference><Reference><Citation>Morello R., Mariani F., Mastrantoni L., et al. Risk factors for post-COVID-19 condition (Long Covid) in children: a prospective cohort study. eClinicalMedicine. 2023;59</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10101848</ArticleId><ArticleId IdType="pubmed">37073325</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazza M.G., De Lorenzo R., Conte C., et al. Anxiety and depression in COVID-19 survivors: role of inflammatory and clinical predictors. Brain Behav Immun. 2020;89:594&#x2013;600.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7390748</ArticleId><ArticleId IdType="pubmed">32738287</ArticleId></ArticleIdList></Reference><Reference><Citation>Postolache T.T., Benros M.E., Brenner L.A. Targetable biological mechanisms implicated in emergent psychiatric conditions associated with SARS-CoV-2 infection. JAMA Psychiatry. 2021;78(4):353&#x2013;354. doi: 10.1001/jamapsychiatry.2020.2795.</Citation><ArticleIdList><ArticleId IdType="doi">10.1001/jamapsychiatry.2020.2795</ArticleId><ArticleId IdType="pubmed">32735332</ArticleId></ArticleIdList></Reference><Reference><Citation>Villalpando J.M.G., Forcelledo H.A., Castillo J.L.B., et al. COVID-19, long COVID syndrome, and mental health sequelae in a Mexican population. Int J Environ Res Public Health. 2022;19(12):6970.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9222368</ArticleId><ArticleId IdType="pubmed">35742219</ArticleId></ArticleIdList></Reference><Reference><Citation>Lyra E Silva N.M., Barros-Arag&#xe3;o F.G.Q., De Felice F.G., Ferreira S.T. Inflammation at the crossroads of COVID-19, cognitive deficits and depression. Neuropharmacology. 2022;209</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8894741</ArticleId><ArticleId IdType="pubmed">35257690</ArticleId></ArticleIdList></Reference><Reference><Citation>Taube M. Depression and brain fog as long-COVID mental health consequences: difficult, complex and partially successful treatment of a 72-year-old patient&#x2014;a case report. Front Psychiatry. 2023;14</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10079873</ArticleId><ArticleId IdType="pubmed">37032935</ArticleId></ArticleIdList></Reference><Reference><Citation>PHOSP-COVID Collaborative Group Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study. Lancet Respir Med. 2022;10(8):761&#x2013;775.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9034855</ArticleId><ArticleId IdType="pubmed">35472304</ArticleId></ArticleIdList></Reference><Reference><Citation>Yavropoulou M.P., Tsokos G.C., Chrousos G.P., Sfikakis P.P. Protracted stress-induced hypocortisolemia may account for the clinical and immune manifestations of Long COVID. Clin Immunol. 2022;245</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9519365</ArticleId><ArticleId IdType="pubmed">36182048</ArticleId></ArticleIdList></Reference><Reference><Citation>Hastie C.E., Lowe D.J., McAuley A., et al. Natural history of long-COVID in a nationwide, population cohort study. Nat Commun. 2023;14(1):3504.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC10263377</ArticleId><ArticleId IdType="pubmed">37311808</ArticleId></ArticleIdList></Reference><Reference><Citation>Whittemore R., Vilar-Compte M., De La Cerda S., et al. Challenges to diabetes self-management for adults with type 2 diabetes in low-resource settings in Mexico City: a qualitative descriptive study. Int J Equity Health. 2019;18(1):133.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6708131</ArticleId><ArticleId IdType="pubmed">31443659</ArticleId></ArticleIdList></Reference><Reference><Citation>Bello-Chavolla O.Y., Antonio-Villa N.E., Fern&#xe1;ndez-Chirino L., et al. Diagnostic performance and clinical implications of rapid SARS-CoV-2 antigen testing in Mexico using real-world nationwide COVID-19 registry data. PLoS One. 2021;16(8)</Citation><ArticleIdList><ArticleId IdType="pmc">PMC8407542</ArticleId><ArticleId IdType="pubmed">34464393</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosa Duque J.S., Wang X., Leung D., et al. Immunogenicity and reactogenicity of SARS-CoV-2 vaccines BNT162b2 and CoronaVac in healthy adolescents. Nat Commun. 2022;13(1):3700.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9240007</ArticleId><ArticleId IdType="pubmed">35764637</ArticleId></ArticleIdList></Reference><Reference><Citation>Fonseca M.H.G., Pinto A.C.M.D., Silva M.F.S., et al. Dynamics of SARS-CoV-2 antibody response to CoronaVac followed by booster dose of BNT162b2 vaccine. Emerg Infect Dis. 2022;28(6):1237&#x2013;1240.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC9155880</ArticleId><ArticleId IdType="pubmed">35421324</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>